TokenPost·
Ligand Pharmaceuticals Raises 2026 Adjusted EPS Outlook After Q3 Beat
The company lifted its adjusted earnings per diluted share range to about $9.50 to $9.75 while keeping its $270 million to $310 million revenue forecast unchanged.
More news
- The BlockHYPE surges 15% as NYSE parent ICE moves to bring Hyperliquid perps to US
- TokenPostEther Rises 1.45% in an Hour to $2,349 on Binance Spot Market
- Crypto BriefingMusk explores SpaceX-Tesla merger as ticker “X” becomes available
- CoinGapeWhat to Expect From MSTR Stock Price After Strategy’s Q3 Earnings Release Today
- TokenPostMedical Properties Trust Revenue Rises 5.3% as Normalized FFO Falls
- TokenPostBorrowing to Short Stocks Nears Five-Year High as Anthropic IPO Could Renew AI Interest